Spectronaut and DIA-NN: A Comparison of their Performance in the Analysis of Lung Adenocarcinoma Biopsies.

Direct data-independent acquisition (DIA) in liquid chromatography-tandem mass spectrometry (LC-MS/MS) has developed into a powerful methodology for proteomics. Herein, we directly compare the performance of two widely used DIA computational platformsSpectronaut and DIA-NNusing paired tumor and peritumor tissue biopsies from human lung carcinoma (LUAD) patients, samples that one would encounter in a clinical research lab in a hospital setting. The evaluations include the following: (1) protein identification depth, (2) quantitative consistency, and (3) differential expression on the same set of LC-MS/MS runs, using nominally identical computational parameters and settings. Both Spectronaut and DIA-NN identified ∼>7600 proteins in the LUAD samples, with 7180 proteins common to both platforms. Spectronaut reported 1250 upregulated proteins and 266 downregulated proteins (tumor versus peritumor), while DIA-NN reported 1819 and 174 proteins, respectively. A total of 1130 differentially expressed proteins (DEPs) were common to both platforms. Of the top 50 DEPs, 34 were shared between Spectronaut and DIA-NN. Two of these DEPsHSPA5 and CAV1were also among the top 50 proteins showing the highest degrees of protein-protein interaction. The DEPs enabled classification of the LUAD patients into three subtypes; the clinical validity of the current subtypes will need to be substantiated in the future with additional LUAD samples and experimentation.